FDA Warns About “Solution” that Does Not Cure Cancer, Obesity-Related Cancers on the Rise, and more

Here are the top stories covered by DocWire News this week in the Hematology & Oncology section. This week, the U.S. Food and Drug Administration (FDA) approved two new drugs, a combination chimeric antigen receptor (CAR) T-cell therapy improves multiple myeloma (MM) survival, and more.

A combination of humanized anti-CD19 and anti-B-cell maturation antigen (BCMA) CAR T-cell therapy resulted in a 95% response rate among patients with relapsed/refractory MM, according to a study published in The Lancet Haematology.

Recent research from the University of Massachusetts Amherst food scientists has found that consuming frying oil may worsen colon cancer and colitis. In their study, they found that feeding frying oil to mice led to heightened inflammation of the colon, tumor growth, gut leakage, and spreading of bacteria and their toxic byproducts into the circulatory system.

The FDA issued a warning to consumers not to purchase or drink Miracle or Master Mineral Solution, Miracle Mineral Supplement, MMS, Chlorine Dioxide Protocol, Water Purification Solution, and other similar products. Miracle Mineral Solution has not been approved by the FDA for any use, but these products have been promoted on social media as a remedy for treating various conditions, including cancer.

The FDA approved two new drugs: Inrebic® (fedratinib) for the treatment of intermediate-2 or high-risk primary or secondary myelofibrosis and Rozlytrek® (entrectinib), a tumor-agnostic treatment for NTRK- and ROS1-positive solid tumors.

A new study observed a shift in the incidence of obesity-associated cancers from older patients to younger ones.

In case you missed it, more hem/onc headlines are featured below: